| Preclinical proof of principle for orally delivered Th17 antagonist miniproteins S Berger, F Seeger, TY Yu, M Aydin, H Yang, D Rosenblum, ... Cell 187 (16), 4305-4317. e18, 2024 | 12 | 2024 |
| Large-scale characterization of drug mechanism of action using proteome-wide thermal shift assays JG Van Vranken, J Li, J Mintseris, TY Wei, CM Sniezek, M Gadzuk-Shea, ... elife 13, RP95595, 2024 | 8 | 2024 |
| Defining the heterogeneous molecular landscape of lung cancer cell responses to epigenetic inhibition C Lin, CM Sniezek, CD McGann, R Karki, RM Giglio, BA Garcia, ... bioRxiv, 2024 | | 2024 |
| Su1733 ORAL IL-23R ANTAGONIST MINIPROTEIN MB1 IS AS EFFECTIVE AS GUSELKUMAB IN A PRECLINICAL MODEL OF COLITIS S Berger, F Seeger, TY Yu, M Aydin, C Glassman, L Arguinchona, ... Gastroenterology 166 (5), S-790, 2024 | | 2024 |
